Abzena, the leading end-to-end integrated contract and development manufacturing organization for complex biologics and bioconjugates, and Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the biopharmaceutical and diagnostics industries, announced a strategic partnership to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations. This alliance offers a streamlined approach for customers looking to rapidly progress therapies into the clinic, or onward into later-stage commercial manufacturing.
The partnership removes the white space in drug development for biopharma drug companies by utilizing a single development and manufacturing team to seamlessly transition from early discovery services (ranging from antibody engineering, developability, formulation development, cell line development, process and analytical development) through clinical and commercial manufacturing of drug substance and drug product. This tight integration of activities facilitates more informed and rapid decision-making, efficient technology transfer, and a reduction in supply chain complexity.
Both Abzena and Argonaut have extensive experience in developing and manufacturing biopharmaceutical programs that span the entire development pathway. By harmonizing Abzena’s comprehensive antibody discovery, development and cGMP manufacturing capabilities with Argonaut’s exemplary sterile fill-finish offering, encapsulates a full-spectrum service model designed to optimize efficiency and accelerate development timelines.
Also Read: X-Chem Strengthens Its Data-Driven Discovery Services With New CBO Appointment
Matt Stober, CEO of Abzena said, “Abzena’s mission is to rapidly move medicines forward to patients in need. Embarking on this strategic partnership with Argonaut further demonstrates our commitment to this mission, marking a significant milestone in our quest to provide streamlined solutions that address the unique needs of our customers. This collaboration signifies a pivotal advancement in biopharmaceutical development and reinforces the shared vision of both our organizations to drive innovation, quality, and speed to market for our customer’s life-changing treatments.
Wayne Woodard, CEO of Argonaut said, “For the past few years, Argonaut and Abzena have been successfully building and strengthening their partnership. Today, we further enhance this collaboration by publicly recognizing the value that our two companies can generate for our clients. Ecosystems are an integral part of our business, and these partnerships are crucial in providing comprehensive support to all our clients, regardless of their size, to ensure efficient and successful delivery of their drugs to patients.”
SOURCE: PRNewswire